Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Therapeutic targeting of CCR1 attenuates established chronic fungal asthma in mice.

Authors: Carpenter, KJ  Ewing, JL  Schuh, JM  Ness, TL  Kunkel, SL  Aparici, M  Miralpeix, M  Hogaboam, CM 
Citation: Carpenter KJ, etal., Br J Pharmacol. 2005 Aug;145(8):1160-72.
Pubmed: (View Article at PubMed) PMID:15951834
DOI: Full-text: DOI:10.1038/sj.bjp.0706243

CC chemokine receptor 1 (CCR1) represents a promising target in chronic airway inflammation and remodeling due to fungus-associated allergic asthma. The present study addressed the therapeutic effect of a nonpeptide CCR1 antagonist, BX-471, in a model of chronic fungal asthma induced by Aspergillus fumigatus conidia. BX-471 treatment of isolated macrophages inhibited CCL22 and TNF-alpha and promoted IL-10 release. BX-471 also increased toll like receptor-9 (TLR9) and decreased TLR2 and TLR6 expression in these cells. When administered daily by intraperitoneal injection, from days 15 to 30 after the initiation of chronic fungal asthma, BX-471 (3, 10, or 30 mg kg(-1)) dose-dependently reduced airway inflammation, hyper-responsiveness, and remodeling at day 30 after conidia challenge. The maximal therapeutic effect was observed at the 10 mg kg(-1) dose. In summary, the therapeutic administration of BX-471 significantly attenuated experimental fungal asthma via its effects on both innate and adaptive immune processes.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 5688155
Created: 2012-02-20
Species: All species
Last Modified: 2012-02-20
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.